Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Assets: 2016-2024

Historic Current Assets for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $113.8 million.

  • Akebia Therapeutics' Current Assets rose 158.03% to $258.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.3 million, marking a year-over-year increase of 158.03%. This contributed to the annual value of $113.8 million for FY2024, which is 3.65% down from last year.
  • Akebia Therapeutics' Current Assets amounted to $113.8 million in FY2024, which was down 3.65% from $118.1 million recorded in FY2023.
  • Akebia Therapeutics' Current Assets' 5-year high stood at $371.4 million during FY2020, with a 5-year trough of $113.8 million in FY2024.
  • Moreover, its 3-year median value for Current Assets was $118.1 million (2023), whereas its average is $139.1 million.
  • As far as peak fluctuations go, Akebia Therapeutics' Current Assets rose by 20.00% in 2020, and later tumbled by 36.20% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Current Assets (MRY) stood at $371.4 million in 2020, then decreased by 27.00% to $271.1 million in 2021, then crashed by 31.70% to $185.2 million in 2022, then plummeted by 36.20% to $118.1 million in 2023, then decreased by 3.65% to $113.8 million in 2024.
  • Its Current Assets was $113.8 million in FY2024, compared to $118.1 million in FY2023 and $185.2 million in FY2022.